

The association of topoisomerase 2 α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients

Hulya Çelenk Erguden¹, Deniz Koksal¹, Funda Demirag², Hulya Bayiz¹, Neslihan Mutluay¹, Bahadır Berktaş¹, Mine Berkoglu¹

¹2nd Chest Diseases Clinic, ²Pathology Department, Ataturk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey

ABSTRACT

Background: Topoisomerase 2 α (Topo 2 α) is a nuclear enzyme that alters the topology of DNA. It's essential for normal chromosome segregation during cellular division. We aimed to investigate the association of Topo 2 α expression with clinical, pathological parameters and prognosis in surgically resected non-small cell lung cancer (NSCLC) patients.

Methods: The study is comprised of 100 surgically resected NSCLC (squamous cell carcinoma in 50 patients, adenocarcinoma in 50 patients). The paraffin embedded tumor sections were retrieved for expression of Topo 2 α . Nuclear and cytoplasmic expression of Topo 2 α was determined by immunohistochemistry. Clinical, pathological data and survival of patients were determined from the hospital files. Median follow-up time was 35 (range, 4-120) months.

Results: Nuclear and cytoplasmic expression of Topo 2 α was positive in 41 (41%) and 66 (66%) patients, respectively. There was no significant association between nuclear or cytoplasmic expression of Topo 2 α and age, gender, smoking history. While nuclear expression was significantly increased in squamous cell carcinoma (P=0.008), OR (95% CI): 3.01 (1.31-6.92), cytoplasmic expression wasn't different. Both nuclear and cytoplasmic expression didn't show any association with tumor diameter, pathological stage, tumor differentiation and relapse. There was no significant association between nuclear or cytoplasmic expression of Topo 2 α and survival. Tumor diameter (P=0.031) and metastasis to N2 lymph nodes (P=0.005) were independent prognostic factors.

Conclusions: There was no association between Topo 2 α expression and prognosis in surgically resected NSCLC patients. Nuclear expression of Topo 2 α was significantly higher in patients with squamous cell carcinoma.

KEY WORDS

Non-small cell lung cancer; topoisomerase 2 α ; prognosis

J Thorac Dis 2012;4(4):352-357. DOI: 10.3978/j.issn.2072-1439.2012.08.04

Introduction

Lung cancer is a group of heterogeneous clinical entities with common molecular and cellular origins, but different accumulated genetic mutations with different clinical behaviors and prognoses (1). The outcome of a lung cancer patient depends on a variety of variables defined as prognostic factors (2). The

recurrence rates of surgically resected non-small cell lung cancer (NSCLC) patients are highly variable changing between 20% to 85% (3). The principal factors related to the recurrence are tumor stage, histology, localization, adequacy of mediastinal dissection and administration of adjuvant chemotherapy. There are also new and promising molecular/biologic markers that are not utilized routinely for determination of prognosis such as regulators of cellular growth (KRAS, EGFR, RB), of the metastatic cascade (TPA, Cyclin-D1, cathepsin) and of apoptosis (p53, bcl-2) (1-4).

Topoisomerase 2 (Topo 2) is a nuclear enzyme that alters the topology of DNA and is essential for normal chromosome segregation at mitosis. In mammalian cells, there are two isoforms as Topo 2 α and Topo 2 β . Topo 2 α is considered a specific marker of cell proliferation in both normal and neoplastic tissues (5). It is also a target for some chemotherapeutic agents in clinical use (6). Previous clinical studies have shown that Topo 2 α

Corresponding to: Deniz Koksal. Ataturk Chest Diseases and Chest Surgery Education and Research Hospital 2nd Chest Diseases Clinic, Sanatoryum Cad. 06290 Kecioren, Ankara, Turkey. Email: dckoksal@gmail.com.

Submitted Jul 1, 2012. Accepted for publication Jul 31, 2012.
Available at www.jthoracdis.com

ISSN: 2072-1439

© Pioneer Bioscience Publishing Company. All rights reserved.

expression reflects several biologic behaviours in human cancers such as lung carcinomas (7,8). In a small study by Guinee *et al.*, Topo 2 α expression was higher in frequency in SCLC compared with NSCLC (8). In a study by Dingemans *et al.*, high expression of Topo 2 α was predictive of worse survival and high expression of Topo 2 β predictive of lower chemotherapy response rates in patients with small cell lung cancer (SCLC) (9).

In this study, we aimed to investigate the association of Topo 2 α expression with clinical (age, gender, smoking history, administration of adjuvant chemotherapy), pathological parameters (tumor histology, stage, tumor diameter, involvement of lymph nodes, differentiation) and prognosis in surgically resected NSCLC patients.

Material and methods

Patients

This study is approved by the local ethic committee of Ataturk Chest Diseases and Chest Surgery Education and Research Hospital. Informed consent waived for this retrospective study. Surgically resected tumor specimens from 100 randomly selected NSCLC patients who were not treated with preoperative chemotherapy were studied. Hospital files were reviewed for clinical data. There were 91 male and 9 female patients with a mean age of 59.7 \pm 10.5 years (range, 37-78 years). All patients underwent lobectomy (82 patients) or pneumonectomy (18 patients) with hilar and mediastinal lymph node dissection. Pathological stage was determined according to the 7th edition of TNM staging system (10). Histopathological diagnosis was squamous cell carcinoma and adenocarcinoma in 50 patients each. There were 5 patients with stage 1a, 28 patients with stage 1b, 21 patients with stage 2a, 21 patients with stage 2b, 25 patients with stage 3a. The clinical and pathological characteristics of patients are seen in Table 1. Twenty-nine patients received adjuvant cisplatin based chemotherapy regimens, 15 patients adjuvant radiotherapy and 6 patients both adjuvant chemotherapy and radiotherapy.

Nine patients who died due to postoperative complications or toxicities due to adjuvant chemotherapies were excluded from survival analysis. Median follow up time was 35 [4-120] months. There were 49 (53.8%) relapses during the follow up period. Mean relapse time was 35.5 \pm 25.7 [3-120] months.

Immunohistochemistry

All slides of the patients were reviewed. Representative blocks were selected for immunohistochemistry. Tissue samples were fixed in 10% buffered formalin embedded in parafin and cut at 6 μ m for immunohistochemistry. Sections were dewaxed in xylene substitute (ThermoScientific) and hydrated with a graded

series of ethanol concentrations and water.

Immunostaining of Topo 2 α was performed using the streptavidin-biotin complex kit (ThermoScientific, Fremont, USA). Sections were incubated with primary antibody solution for Topo 2 α Ab-4 (ThermoScientific) at a dilution of 1:20 for 30 minutes at room temperature. Diaminobenzidine was used as the chromogen. After incubation, the chromogen specimens were counterstained with Harris hematoxylin and coverslipped. Samples of tonsil tissues were used as positive control. Negative controls were performed by substituting without primary antibody.

The intensity of Topo 2 α immunostaining was evaluated by light microscopy (Labsphot-2; Nikon, Tokyo, Japan). The expression of Topo 2 α was evaluated as nuclear and cytoplasmic. More than 10% of nuclear positive cells were considered as nuclear positivity. Cytoplasmic immunoreactivity was evaluated based on the percentage of positive tumor cells and scored as negative: no cytoplasmic Topo 2 α staining, weak (1+): 0-30% staining, moderate (2+): 31-60% staining, and intense (3+): more than 60% staining.

Statistical analysis

Statistical analysis was performed using SPSS for windows release 11.5 package program. Univariate Logistic Regression Analysis was performed to analyze the relation between expression of nuclear or cytoplasmic expression of Topo 2 α and clinical and pathological findings. Survival curves were computed by using method of Kaplan Meier. In order to evaluate the independent prognostic relevance of nuclear and cytoplasmic expression of Topo 2 α , we performed multivariate analysis using Cox Regression model. A value of P<0.05 was accepted as statistically significant.

Results

Nuclear and cytoplasmic expression of Topo 2 α in tumor tissues

Nuclear expression of Topo 2 α was positive in 41 (41%) and negative in 59 (59%) specimens. Cytoplasmic expression of Topo 2 α was positive in 66 (66%) and negative in 34 (34%) specimens. Cytoplasmic expression was weak in 33, moderate in 13 and intense in 20 specimens. Figure 1 demonstrates intranuclear expression of Topo 2 α in an adenocarcinoma and intracytoplasmic expression of Topo 2 α in a squamous cell carcinoma respectively.

The association of Topo 2 α expression with clinical and pathological characteristics

There was not any significant association between nuclear or

Table 1. The clinical and pathological characteristics of patients.

Variables	Number of patients (n)	Proportion	Ranges
Gender			
Female	9	9%	-
Male	91	91%	-
Mean age (years)	-	-	59.7 \pm 10.5 (range, 37-78)
Non-smoker®	9	9%	-
Smoker	90	90%	-
Operation type			
Pneumonectomy	18 (14 left/4 right)	-	-
Lobectomy	82	-	-
Histopathology			
Squamous cell carcinoma	50	-	-
Adenocarcinoma	50	-	-
Mean tumor diameter (cm)			4.9 \pm 2.1 (1-12)
Tumor stage			
1A	5	5%	-
1B	28	28%	-
2A	21	21%	-
2B	21	21%	-
3A	25	21% (N2 involvement in 22 patients)	-
Differentiation			
Well	57	57%	-
Moderate	31	31%	-
Poor	12	12	-
Adjuvant therapy			
Chemotherapy*	29	-	-
Radiotherapy	15	-	-
Chemotherapy + Radiotherapy	6	-	-

*Cisplatin-based chemotherapy regimens.


**Figure 1. Intranuclear expression of topoisomerase 2 α in an adenocarcinoma (A), Intracytoplasmic expression of topoisomerase 2 α in a squamous cell carcinoma (B) (Topo 2 α \times 200).**

Table 2. Multivariate analysis related to survival using Cox regression.

Variables	OR	95% CI	P
Age	0.98	0.95-1.01	0.24
Female [®]	-	-	-
Male	1.04	0.37-2.92	0.92
Non-smoker [®]	-	-	-
Smoker	1.41	0.50-3.93	0.51
Squamous [®]	-	-	-
Adenocarcinoma	1.40	0.78-2.51	0.25
Tumor diameter	1.17	1.01-1.35	0.031*
Tumor stage			
IA [®]	-	-	-
IB	2.23	0.28-17.3	0.44
2A	4.39	0.56-34.1	0.15
2B	1.49	0.17-12.9	0.71
3A	6.82	0.89-52.1	0.06
N0 [®]	-	-	-
N1	1.47	0.74-2.94	0.26
N2	2.79	1.36-5.74	0.005*
Differentiation			
Poor [®]	-	-	-
Moderate	0.41	0.16-1.06	0.06
Well	0.73	0.32-1.67	0.46
Lobectomy [®]	-	-	-
Pneumonectomy	1.57	0.75-3.26	0.22
Adjuvant therapy			
Given [®]	-	-	-
Not given	0.66	0.37-1.20	0.17
Nuclear topo 2 α			
Negative [®]	-	-	-
Positive	1.24	0.69-2.22	0.46
Cytoplasmic topo 2 α			
Negative [®]	-	-	-
+	1.04	0.49-1.22	0.90
++	1.97	0.86-4.47	0.10
+++	1.28	0.57-2.90	0.54

[®]Reference category, *Statistically significant.

cytoplasmic expression of Topo 2 α and patient age, gender, smoking history ($P>0.05$). While cytoplasmic expression of Topo 2 α was not different, nuclear expression was significantly increased in squamous cell carcinoma ($P=0.008$), OR (95% CI): 3.01 (1.31-6.92). Both nuclear and cytoplasmic expression of Topo 2 α did not show any association with tumor diameter, pathological stage, tumor differentiation and presence of relapse.

The association of Topo 2 α expression and survival

The median overall survival was 34 [4-120] months. At the end

of study 47 (51.6%) patients were dead and 44 (48.4%) patients were alive. There wasn't any significant association between nuclear or cytoplasmic expression of Topo 2 α and survival ($P>0.05$).

Multivariate analysis related to survival using Cox regression is shown in Table 2. Tumor diameter ($P=0.031$) and involvement of N2 lymph nodes ($P=0.005$) were independent prognostic factors. They were related with poor prognosis.

Discussion

Topo 2 is an essential nuclear enzyme that catalyzes the changes in the topology of DNA. It plays a critical role during mitosis for chromosome condensation and segregation, in both neoplastic and nonneoplastic cells (5). There are two isoforms of Topo 2 in mammalian cells: Topo 2 α and Topo 2 β . In the experimental studies on cell cycles, Topo 2 α expression was undetectable until the cells reached to late S phase, peaked in G2-M phase and decreased after mitosis. Topo 2 β expression was constant through the cell cycle (11). Studies including specimens of lung carcinoma patients revealed that Topo 2 α gene expression was significantly higher in tumor tissues compared to normal tissues. But Topo 2 β gene expression was not different between tumor tissues and normal lung tissues (7,12,13). Therefore Topo 2 α expression is a specific marker of cell proliferation and is thought to be related to poor prognosis.

There are several studies reporting that high expression of Topo 2 α was associated with poor prognosis in lung cancer patients (9,14). In a study including tumor samples derived from 93 previously untreated SCLC patients, survival was shorter in patients with extensive disease, poorer performance status, and in patients whose tumors expressed high Topo 2 α and Ki67 levels. High Topo 2 β expression was found to be predictive for lower chemotherapy response rates. The authors concluded that immunohistochemical assessment of these markers in diagnostic biopsies may give important prognostic information and may help selecting patients in the worse prognostic categories for novel therapeutic agents (9). Topo 2 α was also studied as a drug resistance marker in advanced NSCLC patients. There wasn't any relation between Topo 2 α expression and response to chemotherapy. But they observed a shorter survival in patients with high Topo 2 α levels. They explained the shorter survival rate with higher Topo 2 α expression, higher proliferation rate and increased aggressiveness (14). In the present study, since we studied patients who had a curative surgery, our hypothesis was "Higher Topo 2 α expression might be related to early recurrence or in other words poorer survival". But we couldn't find a relation between Topo 2 α expression and survival.

Studies investigating the biological difference between NSCLC and SCLC observed a lower Topo 2 α expression in NSCLC compared to SCLC patients (7,8,15). This situation can

be an explanation for the difference in chemosensitivity. Higher Topo 2 α expressing tumors are more chemosensitive than lower Topo 2 α expressing tumors. In a study of Giaccone *et al.*, higher expression of Topo 2 α was correlated not only with sensitivity to Topo 2 α inhibitors, but also with sensitivity to other classes of chemotherapeutic agents. They postulated that Topo 2 α might be an essential component of a common pathway of cell death which is triggered by multiple or all antineoplastic agents (16). In another study involving 103 squamous cell carcinomas of the head and neck, higher Topo 2 α expression was significantly related to better response to chemotherapy, despite the cytotoxic drugs used was not Topo 2 α antagonists (17). In this study we observed, 41% nuclear expression and 66% cytoplasmic expression of Topo 2 α . These ratios are high enough not to be ignored. Whereas most NSCLC patients are resistant to Topo 2 α drugs, it may be possible to predict the minority of tumors which are sensitive. Larger prospective studies comparing the chemotherapy responses in Topo 2 α expressing and not expressing NSCLC are needed. In contrary to the study of Dingemans *et al.* (14), the demonstration of higher chemosensitivity in higher Topo 2 α expressing tumors would be a milestone in managing NSCLC patients.

There are a few studies investigating the difference of Topo 2 α expression in the histological subtypes of NSCLC (13,18). In these studies they analyse Topo 2 α gene expression by PCR method. In the study by Liu *et al.*, Topo 2 α gene expression was significantly higher in squamous cell carcinomas than in adenocarcinomas (18). Conversely to this study, Mirski *et al.* found that Topo 2 α levels were lower in squamous cell carcinomas than in adenocarcinomas (13). In the present study we investigate the intensity of immunostaining Topo 2 α in tumor tissues. We found a significantly higher nuclear expression of Topo 2 α in patients with squamous cell carcinoma.

There are also studies showing the association of Topo 2 α gene expression and tumor differentiation in breast carcinomas, head and neck carcinomas and lung cancer (17-19). In a study including surgically resected tumor specimens from 98 NSCLC patients, Topo 2 α gene expression was significantly higher in moderately and poorly differentiated tumors compared to well differentiated ones. The overexpression of Topo 2 α gene was associated with more aggressive carcinogenesis, accelerated cell proliferation and tumor dedifferentiation. There wasn't any statistically significant relation between Topo 2 α gene expression and gender or pathological tumor stage (18). In our study we couldn't find a relation between Topo 2 α expression and tumoral differentiation.

There are a few studies investigating the association of Topo 2 α expression with clinical parameters such as age and gender. As in this study they did not find any relation (18,20). In this study we didn't find an association between Topo 2 α expression and smoking history. In study of Liu *et al.*, Topo 2 α expression was

higher in smokers (18). The reason for this difference may be a relatively higher ratio of smoking history (90% present study, 63% Liu *et al.*) in the present study.

In conclusion; in this study we determined both the nuclear and cytoplasmic expression of Topo 2 α in tumor specimens of surgically resected NSCLC patients by immunohistochemistry. We investigated the association of both nuclear and cytoplasmic expression of Topo 2 α with clinical (age, gender, smoking history, administration of adjuvant chemotherapy), pathological parameters (tumor histology, stage, tumor diameter, involvement of lymph nodes, differentiation) and prognosis. We couldn't find any association between Topo 2 α expression and clinical findings. Nuclear expression of Topo 2 α was significantly higher in patients with squamous cell carcinoma. There wasn't any association between Topo 2 α expression and survival. As expected tumor diameter and involvement of N2 lymph nodes were independent prognostic parameters in multivariate analysis.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References

1. Brundage MD, Mackillop WJ. Prognostic factors in thoracic malignancies. In: Goldstraw P. eds. IASLC Manual - Staging Manual in Thoracic Oncology. Orange Park, FL, USA: Editorial Rx Press. 2009:129-40.
2. Gospodarowicz MK, O'Sullivan B, Koh ES. Prognostic factors: Principles and applications. In: Peter Goldstraw. eds. IASLC Manual - Staging Manual in Thoracic Oncology. Orange Park, FL, USA: Editorial Rx Press. 2009:111-28.
3. Brundage MD, Mackillop WJ. Lung cancer. In: Gospodarowicz MK HD, Hutter RVP, O'Sullivan B, et al. eds. Prognostic Factors in Cancer. New York: Wiley-Liss, 2001:351-70.
4. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. *Chest* 2002;122:1037-57.
5. Heck MM, Earnshaw WC. Topoisomerase II: A specific marker for cell proliferation. *J Cell Biol* 1986;103:2569-81.
6. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. *J Biol Chem* 1995;270:21429-32.
7. Syahrudin E, Oguri T, Takahashi T, et al. Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer. *Jpn J Cancer Res* 1998;89:855-61.
8. Guinee DG Jr, Holden JA, Benfield JR, et al. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. *Cancer* 1996;78:729-35.
9. Dingemans AM, Witlox MA, Stallaert RA, et al. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. *Clin Cancer Res* 1999;5:2048-58.

10. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. *Chest* 2009;136:260-71.
11. Woessner RD, Mattern MR, Mirabelli CK, et al. Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. *Cell Growth Differ* 1991;2:209-14.
12. Giaccone G, van Ark-Otte J, Scagliotti G, et al. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. *Biochim Biophys Acta* 1995;1264:337-46.
13. Mirski SE, Voskoglou-Nomikos T, Young LC, et al. Simultaneous quantitation of topoisomerase II alpha and beta isoform mRNAs in lung tumor cells and normal and malignant lung tissue. *Lab Invest* 2000;80:787-95.
14. Dingemans AC, van Ark-Otte J, Span S, et al. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. *Lung Cancer* 2001;32:117-28.
15. Kreisholt J, Sorensen M, Jensen PB, et al. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. *Br J Cancer* 1998;77:1469-73.
16. Giaccone G, Gazdar AF, Beck H, et al. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. *Cancer Res* 1992;52:1666-74.
17. Stathopoulos GP, Kapranos N, Manolopoulos L, et al. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck. *Anticancer Res* 2000;20:177-82.
18. Liu D, Huang CL, Kameyama K, Hayashi E, et al. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. *Cancer* 2002;94:2239-47.
19. Nakopoulou L, Lazaris AC, Kavantzias N, et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. *Pathobiology* 2000;68:137-43.
20. Chiappori AA, Zheng Z, Chen T, et al. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. *J Thorac Oncol* 2010;5:484-90.



Cite this article as: Erguden HÇ, Koksall D, Demirag F, Bayiz H, Mutluay N, Berktaş B, Berkoglu M. The association of topoisomerase 2 α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients. *J Thorac Dis* 2012;4(4):352-357. DOI: 10.3978/j.issn.2072-1439.2012.08.04